Stay updated on Ganaxolone in PCDH19 Epilepsy Clinical Trial
Sign up to get notified when there's something new on the Ganaxolone in PCDH19 Epilepsy Clinical Trial page.

Latest updates to the Ganaxolone in PCDH19 Epilepsy Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2 to the page. The funding-status notices from earlier versions (lapse in government funding and related operating-status details) have been removed.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding notice banner about potential delays and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a glossary toggle and updated metadata related to QC status and policy (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). Removed or changed the previous QC label and revision reference (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 replaced v3.3.3 on the page. This appears to be a minor update with no changes to study details or user-facing functionality.SummaryDifference0.1%

- Check63 days agoChange DetectedIntroduces a Locations section with state locations (Arizona, California, Georgia, Indiana, Massachusetts, New Jersey, Ohio) and updates the revision to v3.3.3. Individual state location subsections and the HHS Vulnerability Disclosure text were removed.SummaryDifference0.9%

- Check92 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Ganaxolone in PCDH19 Epilepsy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ganaxolone in PCDH19 Epilepsy Clinical Trial page.